Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

UBS
Deloitte
Moodys
Harvard Business School
Farmers Insurance
Teva
US Department of Justice
Cantor Fitzgerald
Fuji

Generated: July 19, 2018

DrugPatentWatch Database Preview

Novo Nordisk Inc Company Profile

« Back to Dashboard

Summary for Novo Nordisk Inc
International Patents:466
US Patents:32
Tradenames:50
Ingredients:32
NDAs:41
Drug Master File Entries: 3
Patent Litigation for Novo Nordisk Inc: See patent lawsuits for Novo Nordisk Inc

Drugs and US Patents for Novo Nordisk Inc

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Novo Nordisk Inc NORDITROPIN NORDIFLEX somatropin recombinant INJECTABLE;INJECTION 021148-006 Oct 1, 2004 DISCN No No RE41956 ➤ Sign Up Y ➤ Sign Up
Novo Nordisk Inc NPH INSULIN insulin susp isophane beef INJECTABLE;INJECTION 017929-001 Approved Prior to Jan 1, 1982 DISCN No No ➤ Sign Up ➤ Sign Up
Novo Nordisk Inc SAXENDA liraglutide recombinant SOLUTION;SUBCUTANEOUS 206321-001 Dec 23, 2014 RX Yes Yes RE46363 ➤ Sign Up Y ➤ Sign Up
Novo Nordisk Inc NOVOLOG FLEXTOUCH insulin aspart recombinant INJECTABLE;SUBCUTANEOUS 020986-005 Oct 31, 2013 DISCN Yes No 6,899,699 ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for Novo Nordisk Inc

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Novo Nordisk Inc NOVOLOG MIX 70/30 PENFILL insulin aspart protamine recombinant; insulin aspart recombinant INJECTABLE;SUBCUTANEOUS 021172-003 Nov 1, 2001 5,834,422 ➤ Sign Up
Novo Nordisk Inc NOVOLOG MIX 70/30 PENFILL insulin aspart protamine recombinant; insulin aspart recombinant INJECTABLE;SUBCUTANEOUS 021172-002 Nov 1, 2001 5,840,680 ➤ Sign Up
Novo Nordisk Inc NORDITROPIN FLEXPRO somatropin recombinant INJECTABLE;INJECTION 021148-008 Mar 1, 2010 5,849,700 ➤ Sign Up
Novo Nordisk Inc NOVOLOG MIX 70/30 FLEXPEN insulin aspart protamine recombinant; insulin aspart recombinant INJECTABLE;SUBCUTANEOUS 021172-004 May 3, 2002 5,618,913*PED ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for NOVO NORDISK INC drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Tablets 1 mg/500 mg and 2 mg/500 mg ➤ Subscribe 2009-04-09
➤ Subscribe Injection 18 mg/3 mL prefilled syringe ➤ Subscribe 2016-12-12
➤ Subscribe Vaginal Tablets 10 mcg ➤ Subscribe 2013-01-02

Non-Orange Book US Patents for Novo Nordisk Inc

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,226,990 Extendin derivatives ➤ Sign Up
7,235,627 Derivatives of GLP-1 analogs ➤ Sign Up
6,011,007 Acylated insulin ➤ Sign Up
8,097,698 Derivatives of GLP-1 analogs ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Supplementary Protection Certificates for Novo Nordisk Inc Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
/2000 Austria ➤ Sign Up PRODUCT NAME: INSULIN ASPART/PROTAMIN; NAT. REGISTRATION NO/DATE: EU/1/00/142/001-008 20000801; FIRST REGISTRATION: LI 55414-55416 20000623
213 Luxembourg ➤ Sign Up PRODUCT NAME: INSULINE DEGLUDEC SOUS TOUTES LES FORMES PROTEGEES PAR LE BREVET DE BASE
/2000 Austria ➤ Sign Up PRODUCT NAME: LANTUS - INSULIN GLARGIN; REGISTRATION NO/DATE: EU/1/00/134/001 - EU/1/00/134/007 20000609
0880 Netherlands ➤ Sign Up PRODUCT NAME: SNELWERKENDE INSULIN ASPART; REGISTRATION NO/DATE: EU/1/16/1160 20170109
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Johnson and Johnson
UBS
Cerilliant
McKinsey
Colorcon
Daiichi Sankyo
Chubb
Cantor Fitzgerald
Fish and Richardson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.